EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

Efficacy of Dupilumab for the Treatment of Moderate‐to‐Severe Nail Dystrophy in Children

WeiQi Ren, ChaoYang Miao, YuanXiang Liu, YunLiu Chen, ZhaoYang Wang, Xin Xiang, XinRong Zhao, JiaYing Li, ZiGang Xu

Journal of Cosmetic Dermatology · 2026-11 · 25 (11)

DOI: 10.1111/jocd.71307 ↗

At a glance

Journal article in Journal of Cosmetic Dermatology, published online on 2026-11-18. Written by WeiQi Ren and 8 co-authors. 32 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Key Research and Development Program of China, Natural Science Foundation of Beijing Municipality.

AstrattDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Nail dystrophy occurs most frequently in children and is often refractory to conventional topical and systemic medications. Consequently, there is a need for novel treatment options for moderate‐to‐severe nail dystrophy in children.

Objective

This study aims to evaluate the treatment response to dupilumab among pediatric moderate‐to‐severe nail dystrophy patients.

Methods

A retrospective study was conducted among pediatric patients who were treated moderate‐to‐severe nail dystrophy between September 2023 and January 2026. All patients received the standard dose of dupilumab. Treatment response was assessed using the five‐point global improvement scale (GIS) at Weeks 8, 16, 24, 36, and 52.

Results

A total of 13 patients with moderate‐to‐severe nail dystrophy were included (mean age 7.9 years [±3.4], 69.2% males, mean disease duration 2.6 years [±2.0]). No patient had atopic dermatitis or psoriasis. Dupilumab was found to have promising efficacy, achieving complete response in 9/13 (69.2%). The mean GIS score improved to 1.2, 1.9, 3.0, 3.8, and 4.0 at Weeks 8, 16, 24, 36, and 52, respectively. No treatment‐related adverse events were observed.

Conclusion

The findings indicate that dupilumab may represent a potential therapeutic option for moderate‐to‐severe nail dystrophy in children, even in the absence of atopic dermatitis.

Funding

  • National Key Research and Development Program of China
  • Natural Science Foundation of Beijing Municipality

Cite

APA

Ren, W., Miao, C., Liu, Y., Chen, Y., Wang, Z., Xiang, X., Zhao, X., Li, J., & Xu, Z. (2026). Efficacy of Dupilumab for the Treatment of Moderate‐to‐Severe Nail Dystrophy in Children. Journal of Cosmetic Dermatology, 25(11). https://doi.org/10.1111/jocd.71307

Vancouver

Ren W, Miao C, Liu Y, Chen Y, Wang Z, Xiang X, et al. Efficacy of Dupilumab for the Treatment of Moderate‐to‐Severe Nail Dystrophy in Children. Journal of Cosmetic Dermatology. 2026;25(11). doi:10.1111/jocd.71307

BibTeX
@article{Ren2026,
  author = {Ren, WeiQi and Miao, ChaoYang and Liu, YuanXiang and Chen, YunLiu and Wang, ZhaoYang and Xiang, Xin and Zhao, XinRong and Li, JiaYing and Xu, ZiGang},
  title = {Efficacy of Dupilumab for the Treatment of Moderate‐to‐Severe Nail Dystrophy in Children},
  journal = {Journal of Cosmetic Dermatology},
  year = {2026},
  volume = {25},
  number = {11},
  doi = {10.1111/jocd.71307}
}
Start for free →